Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Shares Outstanding (Weighted Average) (2020 - 2025)

Oncology Institute (TOI) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $97.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 29.06% year-over-year to $97.5 million, compared with a TTM value of $97.5 million through Sep 2025, up 29.06%, and an annual FY2024 reading of $75.0 million, up 1.76% over the prior year.
  • Shares Outstanding (Weighted Average) was $97.5 million for Q3 2025 at Oncology Institute, up from $93.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $97.5 million in Q3 2025 and bottomed at $62.9 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $74.4 million, with a median of $73.7 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 1118.89% in 2021, then increased 0.27% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $66.2 million in 2021, then rose by 9.91% to $72.8 million in 2022, then grew by 1.31% to $73.7 million in 2023, then grew by 1.76% to $75.0 million in 2024, then grew by 29.89% to $97.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for TOI at $97.5 million in Q3 2025, $93.2 million in Q2 2025, and $77.1 million in Q1 2025.